LFSC
F/m Emerald Life Sciences Innovation ETF
F/m Emerald Life Sciences Innovation ETF aims to provide investors with long-term capital appreciation by investing in companies focused on innovations in the life sciences sector.
US
EQUITY
Active
MANAGEMENT STYLE
$ 129.3 M
ASSETS UNDER MGMT
79 bp
EXPENSES
Fund Basics
| Inception date | Oct 30, 2024 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| TRAVERE THERAPEUTICS, INC. | 7.8 % |
| SPYRE THERAPEUTICS INC | 7.4 % |
| COGENT BIOSCIENCES INC | 7.2 % |
| CORCEPT THERAPEUTICS INC | 6.8 % |
| LIVANOVA PLC | 6.7 % |
| GUARDANT HEALTH, INC. | 5.9 % |
| BILLIONTOONE INC CL A | 4.9 % |
| CYTOKINETICS INC | 3.8 % |
| MIRUM PHARMACEUTICALS, INC. | 3.6 % |
| AXSOME THERAPEUTICS, INC. | 3.4 % |
Constituent Breakdown
| Number of holdings | 37 |
| Herfindahl-Hirschman Index | 442 |
| Wgt avg mkt cap (mns) | $6,631 |
| Large cap (>$10bn) | 18.2% |
| Mid cap ($2-10bn) | 60.8% |
| Small cap (<$2bn) | 17.2% |
| Developed mkts. | 99.5% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 92.1 % |
 |
BRITAIN | 6.7 % |
 |
SINGAPORE | 0.7 % |
Historical Performance
Standardized Performance (as of 07/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 24.4% | 88.0% | -- | -- | -- | -- | -- | 40.9% |
| Dividend Yield | 0.0% | 0.0% | -- | -- | -- | -- | -- | 0.0% |
| Total Returns | 24.4% | 88.0% | -- | -- | -- | -- | -- | 40.9% | Ann. Volatility | 27.1% | 27.3% | -- | -- | -- | -- | -- | 29.0% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.17 | 30% |
| MSCI EAFE | 0.92 | 28% |
| MSCI Emg Mkts | 0.51 | 21% |
Liquidity Measures
| Avg. volume (000) | 6 |
| ADV traded (mns) | $0 |
| Turnover | 0.2% |
| Avg. Bid/Ask (% of price) | 0.43% |
Technical Indicators
| 30d moving avg. (EMA) | $44.53 |
| Relative strength (RSI) | 58 |
| MACD/Signal | 0.69/0.89 |
| Bollinger Bands (Upper/Lower) | $47.25/$44.23 |
| Short interest (% of AUM) | 0.0% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. LFSC |
Expenses vs. LFSC |
ALTAR Score™ vs. LFSC |
|---|---|---|---|---|
| SPIT | F/m Emerald Special Situations ETF | 19.7% | +26 bp | -0.2% |
| HELX | Franklin Genomic Advancements ETF | 16.5% | -29 bp | -0.9% |
| HLTH | Tema Healthcare AI ETF | 14.8% | -4 bp | +0.6% |
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 14.7% | -19 bp | -1.2% |
| XBI | State Street SPDR S&P Biotech ETF | 13.5% | -44 bp | -0.2% |
| SBIO | ALPS Medical Breakthroughs ETF | 12.3% | -29 bp | 0.0% |
| EKG | First Trust Nasdaq Lux Digital Health Solutions ETF | 11.9% | -14 bp | +0.9% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 10.7% | -23 bp | +1.6% |
| FXH | First Trust Health Care AlphaDEX Fund | 10.1% | -17 bp | +4.9% |
Risk and Returns: LFSC vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 8/9/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
0.0%
ALTAR SCORE™
PERCENTILE
AVOID
ETFRC RATING
There are 1,402 funds in the US Equity category with an average
ALTAR Score™ of 5.2% and a standard deviation
of 2.0%. LFSC's ALTAR Score™ is approximately 0.0 standard
deviations above the category average. This places LFSC in the percentile
among funds in the category.
Sell-Side Consensus
$46.26
PRICE TARGET
-2.1%
UPSIDE